Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgentex Group. Regulatory News (AGFX)

  • This share is currently suspended. It was suspended at a price of 2.45
  • There is currently no data for AGFX

Trading Statement

26 Jan 2023 07:00

RNS Number : 8690N
Argentex Group PLC
26 January 2023
 

26 January 2023

 

Argentex Group PLC

 

("Argentex" or the "Group")

 

Trading Update and Board Change

 

 

Argentex Group PLC (AIM: AGFX), the international provider of foreign exchange services to institutions, corporates and high net worth private individuals, today issues a trading update for the 9 month period ended 31 December 2022.*

Following the update on 12 December 2022 in which Argentex announced that revenue and earnings would be ahead of expectations for the period, the Group now confirms that trading has remained strong and expects to report nine month revenues of £41m, a 63% increase compared to the same period last year (FY2021: £25m)*. 

The Group's strategy to invest in order to build scale and drive profitable growth is delivering according to plan, with operating margins ahead of management expectations. Client demand remains strong with the number of corporate clients trading increasing by 12% to 1,595 (FY2021: 1,424)*.

The Group is making good progress with its three pillared growth strategy; investment in people, technology and overseas expansion, and is currently experiencing robust trading across all products and geographies. The market backdrop has improved with global interest rate differentials returning and this, coupled with an enhanced product mix, has driven the continued strong performance from the core FX offering.

This balanced approach to investment in technology delivered solid returns in the period with a 65% increase in clients trading on the new online platform. This is the first in a suite of technology enabled products to be launched, driven by demand from institutional and corporate clients, providing improved efficiency and the 'right tech, right touch'. As previously reported, the overseas expansion continues to deliver positive momentum allowing Argentex to capitalise on this significant and growing global market opportunity with both new and existing customers.

Argentex continues to focus on its customer service proposition by attracting market-leading talent. In line with its accelerated growth plans, Argentex will continue to invest to double the footprint of its UK and European headquarters over H1 2023.

Board Change

Having completed her initial term in July 2022, Lena Wilson, Senior Independent Director, has advised the Board she will be stepping down from the Board on 28 February 2023 to devote more time to her other business interests.

 

*the Group has changed to a 31 December year end and for this period will report audited 9 months to 31 December 2022. FY2022 refers to the period from 1 April 2022 to 31st December 2022. FY2021 refers to the 9 month period ended 31 December 2021. Revenues generated in the twelve months to 31 December 2022 are £50.4m, an increase of 54% compared to the same period in the prior year (12 months to December 2021 £32.8 m).

 

Harry Adams, CEO of Argentex, commented: 

 

"I'm delighted to report a record year for Argentex, defined by a 63% increase in Group revenues and strong client growth. Our focused three pillared growth strategy is delivering results across all business units as we unlock long-term sustainable growth potential."

 

"There is clear momentum behind our business and we are pleased that the investments we have made in Argentex over recent years have enabled us to again exceed market expectations. We remain focused on delivering positive results for our clients, employees and shareholders. Our outlook and focus on sustainable, diversified growth remains unchanged and, whilst remaining vigilant of the current macroeconomic backdrop, we look forward to the year ahead with confidence."

 

"On behalf of the Board I would like to thank Lena Wilson for her invaluable contribution to Argentex during the initial phase of our journey as a listed business. We wish her every success for the future."

 

 

Argentex expects to report its year end results for the 9 months ended 31 December 2022 in April 2023.

 

 

For further information, please contact:

 

Argentex Group PLC

Harry Adams - Chief Executive Officer

Jo Stent - Chief Financial Officer

investorrelations@argentex.com

 

FTI Consulting (Financial PR)

Ed Berry / Ambrose Fullalove / Jenny Boyd

argentex@fticonsulting.com

 

Singer Capital Markets (Nominated Adviser and Broker)

Tom Salvesen / James Maxwell / Justin McKeegan

020 7496 3000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDELFLXFLFBBD
Date   Source Headline
23rd Apr 202510:30 amRNSStatement regarding Argentex Group plc
23rd Apr 20259:48 amRNSForm 8.3 - Argentex Group plc
23rd Apr 20257:00 amRNSHolding(s) in Company
23rd Apr 20257:00 amRNSResponse to Media Speculation & Financial Position
22nd Apr 20257:40 amRNSSuspension - Argentex Group Plc
22nd Apr 20257:15 amRNSFinancial Position & Suspension of trading
15th Apr 202510:30 amRNSPublication of Annual Report and Notice of AGM
11th Apr 20254:35 pmRNSDirector/PDMR Shareholding
7th Apr 202510:21 amRNSDirector/PDMR Shareholding
4th Apr 20259:31 amRNS-RNotice of Investor Presentation
3rd Apr 20253:51 pmRNSDirector/PDMR Shareholding
2nd Apr 20254:33 pmRNSResults of GM, Grant of Awards, PDMR Notifications
2nd Apr 202512:55 pmRNSAppointment of Non-Executive Director
2nd Apr 20257:00 amRNSFinal Results
19th Mar 20257:00 amRNSNotice of Full Year Results
17th Mar 20253:00 pmRNSShareholder Circular & Notice of General Meeting
21st Jan 20257:00 amRNSTrading Update
4th Dec 202412:00 pmRNSDirector/PDMR Shareholding
9th Oct 20244:00 pmRNSCancellation of Long-Term Incentive Plan
3rd Oct 20243:00 pmRNSDirector / PDMR Dealing
1st Oct 202411:00 amRNSDirector / PDMR Dealing
18th Sep 20247:01 amRNSAppointment of Non-Executive Director
18th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
14th Aug 20247:00 amRNSNotice of Interim Results & Investor Presentation
9th Jul 20247:00 amRNSHalf year trading update
19th Jun 20245:34 pmRNSResult of AGM
6th Jun 20247:00 amRNSInvestor Presentation of FY 2023 Results
4th Jun 20247:00 amRNSAGFX secures Australian Financial Services License
17th May 20243:30 pmRNSHolding(s) in Company
13th May 20246:20 pmRNSDirector/PDMR Dealings
13th May 20241:45 pmRNSPublication of Annual Report and Notice of AGM
9th May 20246:00 pmRNSResult of Placing and Retail Offer
9th May 202410:40 amRNSDirector / PDMR Dealing
3rd May 20247:00 amRNSRetail Offer
2nd May 20245:55 pmRNSResults of Placing
2nd May 20247:01 amRNSProposed Fundraise
2nd May 20247:00 amRNSFull Year Results For the Year Ended 31/12/2023
17th Apr 20247:00 amRNSHolding(s) in Company
27th Feb 20247:00 amRNSHolding(s) in Company
23rd Feb 20247:00 amRNSHolding(s) in Company
14th Feb 20247:00 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading Update and CFO appointment
23rd Nov 20237:00 amRNSDirector/PDMR Dealing
21st Nov 20234:12 pmRNSDirector/PDMR Dealing
16th Nov 20239:23 amRNSAppointment of Non-executive Director
10th Nov 20237:00 amRNSTrading Statement
9th Nov 20233:18 pmRNSStandard form for notification of major holdings
9th Nov 20237:00 amRNSBoard Change
6th Nov 20239:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.